Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) on October 10, 2013. The report details a corporate governance action taken on the same date regarding the company's capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change to the company's Articles of Incorporation.
Material Changes
On October 10, 2013, the company filed a Certificate of Amendment to its Articles of Incorporation with the following changes:
- Common Stock: Authorized shares increased from 100,000,000 to 200,000,000.
- Preferred Stock: Authorization created for 5,000,000 shares (previously, no preferred stock was authorized).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is a procedural notice of the amendment to the Articles of Incorporation.
Investor Verification Checklist
- Verify the exact number of shares issued versus authorized following this amendment.
- Confirm if any preferred stock has been issued or if the authorization remains unutilized.
- Review subsequent filings for any dilution impact on existing common shareholders.